P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study
Paul G. Richardson,Philippe Moreau,Andrzej Jakubowiak,Thierry Facon,Sundar Jagannath,Ravi Vij,Donna E. Reece,Darrell White,Marc S. Raab,Lotfi Benboubker,Jean-François Rossi,Claire Tsao,John Fry,David Berman,Anil K. Singhal,Sagar Lonial +15 more
TL;DR: In a dose-escalation phase 1 study that evaluated the combination of elotuzumab (5, 10, and 20 mg/kg), lenalidomide, and dexamethasone, the maximum tolerated dose was not reached, and the combination showed encouraging clinical activity in patients with advanced MM.
Journal ArticleDOI
Complete genome sequence of Polynucleobacter necessarius subsp. asymbioticus type strain (QLW-P1DMWA-1T)
Linda Meincke,Linda Meincke,Alex Copeland,Alla Lapidus,Susan Lucas,Kerrie W. Berry,Tijana Glavina del Rio,Nancy Hammon,Eileen Dalin,Hope Tice,Sam Pitluck,Paul G. Richardson,David Bruce,David Bruce,Lynne Goodwin,Lynne Goodwin,Cliff Han,Cliff Han,Roxanne Tapia,Roxanne Tapia,John C. Detter,John C. Detter,Jeremy Schmutz,Thomas Brettin,Thomas Brettin,Frank W. Larimer,Frank W. Larimer,Miriam Land,Miriam Land,Loren Hauser,Loren Hauser,Nikos C. Kyrpides,Natalia Ivanova,Markus Göker,Tanja Woyke,Qinglong L. Wu,Matthias Pöckl,Martin W. Hahn,Hans-Peter Klenk +38 more
TL;DR: The features of P. necessarius asymbioticus are described together with the complete genome sequence and annotation, which is the first completed genome sequence of the genus Polynucleobacter to be published and was sequenced as part of the DOE Joint Genome Institute Community Sequencing Program 2006.
Journal ArticleDOI
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma
Erik H. van Beers,Martin H. van Vliet,Rowan Kuiper,Leonie de Best,Kenneth C. Anderson,Ajai Chari,Sundar Jagannath,Andrzej Jakubowiak,Shaji Kumar,Joan Levy,Daniel Auclair,Sagar Lonial,Donna E. Reece,Paul G. Richardson,David S. Siegel,A. Keith Stewart,Suzanne Trudel,Ravi Vij,Todd M. Zimmerman,Rafael Fonseca +19 more
TL;DR: SKY92 best predicted survival (HR = 8.2) and classified the largest fraction of patients (21%) as high risk and the combination SKY92/ISS for identification of three classes; low risk (42%), intermediate risk (37%) and high risk (21%).
Journal ArticleDOI
Percutaneous dilational and surgical tracheostomy in burn patients: incidence of complications and dysphagia.
Sarah T. Smailes,Sarah T. Smailes,M. Ives,Paul G. Richardson,Rebecca V. Martin,Peter Dziewulski,Peter Dziewulski +6 more
TL;DR: It is concluded that there is no difference in the complication rates for PDT and OST in the authors' burn patients and recommends early closure of neck burns and tracheostomy through fully adherent autograft or at least 10 days after grafting to reduce stomal infections.
Journal ArticleDOI
Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β -catenin/TCF pathway
Hiroshi Yasui,Teru Hideshima,Hiroshi Ikeda,Hiroshi Ikeda,Enrique M. Ocio,Tanyel Kiziltepe,Sonia Vallet,Yutaka Okawa,Paola Neri,Kumar Sukhdeo,Kumar Sukhdeo,Klaus Podar,D Chauhan,Paul G. Richardson,Noopur Raje,Daniel R. Carrasco,Daniel R. Carrasco,KC Anderson +17 more
TL;DR: It is demonstrated that SDX-308 (CEP-18082) has more potent cytotoxicity than R-etodolac against both MM cell lines and patient MM cells, including tumor cells resistant to conventional and novel therapies.